Chicago, IL -- (SBWIRE) -- 08/06/2015 -- After 30 years of development, the China's diagnostic reagent industry achieved a market size of nearly RMB 20 billion in 2014, a YoY growth of 15.7%. Currently nearly 90% downstream users of China's diagnostic reagent market comes from hospitals.

There's still a huge growth potential in China's diagnostic reagent industry. China accounts for 20% of total population worldwide, but only take up 7% of global diagnostic reagent market in 2014. The average diagnostic reagent expense in China is only around $3, far below the average of $28 in the developed countries.

Complete report is available at
http://www.rnrmarketresearch.com/research-on-china-diagnostic-reagent-industry-2015-market-report.html

Currently there are about 300 diagnostic reagent enterprises in China and the industry concentration is still low. Large companies in China include: KHB, Da An Gene, Maker, HTA etc. Foreign brands accounts for over 50% of China's diagnostic reagent market in 2014, especially in high-end fields. The market share of domestic enterprises mainly comes from biochemical reagents.

China has fulfilled the import substitution of biochemical reagents, intensified competition has largely squeezed the profits in this subfield. Chemiluminescence Immunoassay (CLIA) and molecular diagnosis will be the most promising subfields in China's diagnostic reagent industry.

New Industries Biomedical Engineering Co., Ltd is the leading CLIA enterprise in China. Currently the company owns 102 chemiluminescent reagents and 8 models of CLIA analyzer. The company achieved reagents sales of RMB 331 million and reagents products have exported to Swiss, France, and Italy etc.

Zeesan Biotech is the leading molecular diagnosis enterprise in China. The company achieved molecular diagnosis reagents sales of RMB 11.85 million in 2014. Zeesan's product covers infectious disease (mainly phthisis), tumor (mainly leukemia) and genetic disease.

Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=392985

Table of Contents

1 Overview
1.1 Classification
1.2 Policy
1.3 Industry Chain

2 Market Landscape
2.1 Overview
2.2 Market Segment
2.2.1 Immuno diagnosis
2.2.2 Molecular Diagnosis
2.2.3 Biochemical Diagnosis
2.3 Competition
2.4 Import & Export
2.4.1 Import
2.4.2 Export

3 Major Enterprises
3.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
3.2 Beijing Strong Biotechnologies, Inc (BSBE)
3.3 Da An Gene
3.4 Fosun Pharmaceutical
3.5 Beijing Leadman Biochemistry Co., Ltd.
3.6 Livzon Pharmaceutical Group Inc.
3.7 Mindray Medical
3.8 Biosino Bio-Technology & Science Inc.
3.9 Maker Biotechnology
3.10 Sinocare
3.11 Beijing Kinghawk Pharmaceutical Co., Ltd.
3.12 Bohui Innovation
3.13 Health BioMed
3.14 Wondfo
3.15 Thalys
3.16 SHINVA
3.17 Humanwell Healthcare
3.18 HTA CO. LTD
3.19 New Indutries Biomedical Engineering
3.20 Sichuan Xincheng Biological
3.21 MultiSciences Biotech
3.22 Surexam
3.23 Shanghai Kexin Biotech
3.24 Shanghai Fenghui Medical Science and Technology
3.25 Beijing The Place Bio-Tech
3.26 Beijing The Place Bio-Tech
3.27 Shanghai GenePharma
3.28 Suzhou GenePharma
3.29 EasyDiagnosis Biomedicine
3.30 King Diagnostic Technology
3.31 Zeesan Biotech
3.32 Baibo Biotechnology
3.33 Nymphavn Biotechnology
3.34 Shuguang HZK Biological Technology
3.35 Medicalsystem Biotechnology